Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury

被引:81
作者
Ma, J
Weisberg, A
Griffin, JP
Vaughan, DE
Fogo, AB
Brown, NJ
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Nephrol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
关键词
aldosterone; plasminogen activator inhibitor-1; angiotensin;
D O I
10.1038/sj.ki.5000201
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This study tests the hypothesis that plasminogen activator inhibitor-1 (PAI-1) contributes to aldosterone-induced renal and cardiac injury. The effects of 12-week aldosterone (2.8 mu g/day)/salt (1% drinking water) versus vehicle/salt on renal and cardiac histology and mRNA expression were determined in wild-type (WT) and PAI-1 deficient (PAI-1((-/-))) mice. Systolic blood pressure was similar in aldosterone-infused WT and PAI-1((-/ -)) mice until 12 weeks, when it was significantly higher in the WT mice. At 12 weeks, urine volume, sodium excretion, and sodium/potassium ratio were similarly increased in the two aldosterone-infused groups. In contrast, urine albumin excretion was greater in aldosterone-infused WT mice (mean +/- s.d.: 699.0 +/- 873.0 mu g/24 h) compared to vehicle-infused WT (23.6 +/- 9.0 mu g/24 h, P = 0.003) or aldosterone-infused PAI-1(()-/-) mice (131.6 +/- 110.6 mu g/24 h, P = 0.007). Aldosterone increased glomerular area to a greater extent in WT (4651 +/- 577 versus 3278 +/- 488 mu m(2)/glomerulus in vehicle-infused WT, P < 0.001) than in PAI-1((-/-)) mice (3713 +/- 705 mu m(2)/glomerulus, P < 0.001 versus aldosterone-infused WT), with corresponding mesangial expansion. Renal collagen content was also increased in aldosterone-infused WT versus PAI-1(( -/-)) mice. In WT mice, aldosterone increased renal mRNA expression of PAI-1, collagen I, collagen III, osteopontin, fibronectin, monocyte chemoattractant protein-1 (MCP-1), and F4/80 (all P < 0.05), but not transforming growth factor beta (TGF-beta). In PAI-1((-/-)) mice, aldosterone increased renal expression of collagen I, osteopontin, fibronectin, and MCP-1, and tended to increase collagen III. Renal osteopontin expression was diminished in aldosterone-treated PAI-1((-/-)) compared to aldosterone-treated WT mice (P = 0.05). Aldosterone induced cardiac hypertrophy but not fibrosis in WT and PAI-1((-/-)) mice. PAI-1 contributes to aldosterone-induced glomerular injury.
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 52 条
[31]   PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction [J].
Oda, T ;
Jung, YO ;
Kim, HS ;
Cai, XH ;
López-Guisa, JM ;
Ikeda, Y ;
Eddy, AA .
KIDNEY INTERNATIONAL, 2001, 60 (02) :587-596
[32]   Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury [J].
Oestreicher, EM ;
Martinez-Vasquez, D ;
Stone, JR ;
Jonasson, L ;
Roubsanthisuk, W ;
Mukasa, K ;
Adler, GK .
CIRCULATION, 2003, 108 (20) :2517-2523
[33]   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J].
Pitt, B ;
Remme, W ;
Zannad, F ;
Neaton, J ;
Martinez, F ;
Roniker, B ;
Bittman, R ;
Hurley, S ;
Kleiman, J ;
Gatlin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1309-1321
[34]   Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy - The 4E-left ventricular hypertrophy study [J].
Pitt, B ;
Reichek, N ;
Willenbrock, R ;
Zannad, F ;
Phillips, RA ;
Roniker, B ;
Kleiman, J ;
Krause, S ;
Burns, D ;
Williams, GH .
CIRCULATION, 2003, 108 (15) :1831-1838
[35]   The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].
Pitt, B ;
Zannad, F ;
Remme, WJ ;
Cody, R ;
Castaigne, A ;
Perez, A ;
Palensky, J ;
Wittes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717
[36]   RETRACTED: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study (Retracted article see vol 23, pg 818, 2006) [J].
Rachmani, R ;
Slavachevsky, I ;
Amit, M ;
Levi, Z ;
Kedar, Y ;
Berla, M ;
Ravid, M .
DIABETIC MEDICINE, 2004, 21 (05) :471-475
[37]   Angiotensin AT1 receptor subtype as a cardiac target of aldosterone -: Role in aldosterone-salt-induced fibrosis [J].
Robert, V ;
Heymes, C ;
Silvestre, JS ;
Sabri, A ;
Swynghedauw, B ;
Delcayre, C .
HYPERTENSION, 1999, 33 (04) :981-986
[38]   BIOLOGICAL DETERMINANTS OF ALDOSTERONE-INDUCED CARDIAC FIBROSIS IN RATS [J].
ROBERT, V ;
SILVESTRE, JS ;
CHARLEMAGNE, D ;
SABRI, A ;
TROUVE, P ;
WASSEF, M ;
SWYNGHEDAUW, B ;
DELCAYRE, C .
HYPERTENSION, 1995, 26 (06) :971-978
[39]   Aldosterone: A mediator of myocardial necrosis and renal arteriopathy [J].
Rocha, R ;
Stier, CT ;
Kifor, I ;
Ochoa-Maya, MR ;
Rennke, HG ;
Williams, GH ;
Adler, GK .
ENDOCRINOLOGY, 2000, 141 (10) :3871-3878
[40]   Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart [J].
Rocha, R ;
Martin-Berger, CL ;
Yang, PC ;
Scherrer, R ;
Delyani, J ;
McMahon, E .
ENDOCRINOLOGY, 2002, 143 (12) :4828-4836